Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Endocr Pract ; 29(9): 681-685, 2023 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-37301375

RESUMO

OBJECTIVE: The effects of diabetes medications on COVID-19 hospitalization outcomes have not been consistent. We sought to determine the effect of metformin, dipeptidyl peptidase-4 inhibitors (DPP-4i), and insulin on admission to the intensive care unit (ICU), need for assisted ventilation, development of renal insufficiency, and mortality in patients admitted with COVID-19 infection after controlling for clinical variables and other relevant diabetes-related medications in patients with type 2 diabetes mellitus (DM). METHODS: This was a retrospective study of patients hospitalized with COVID-19 from a single hospital system. Univariate and multivariate analyses were performed that included demographic data, glycated hemoglobin, kidney function, smoking status, insurance, Charlson comorbidity index, number of diabetes medications, and use of angiotensin-converting enzyme inhibitors and statin prior to admission and glucocorticoids during admission. RESULTS: A total of 529 patients with type 2 DM were included in our final analysis. Neither metformin nor DPP4i prescription was associated with ICU admission, need for assisted ventilation, or mortality. Insulin prescription was associated with increased ICU admission but not with need for assisted ventilation or mortality. There was no association of any of these medications with development of renal insufficiency. CONCLUSIONS: In this population, limited to type 2 DM and controlled for multiple variables that have not been consistently studied (such as a measure of general health, glycated hemoglobin, and insurance status), insulin prescription was associated with increased ICU admission. Metformin and DPP4i prescriptions did not have an association with the outcomes.


Assuntos
COVID-19 , Diabetes Mellitus Tipo 2 , Dipeptidases , Inibidores da Dipeptidil Peptidase IV , Metformina , Insuficiência Renal , Humanos , Metformina/uso terapêutico , Diabetes Mellitus Tipo 2/complicações , Hipoglicemiantes/uso terapêutico , Insulina/uso terapêutico , Dipeptidases/uso terapêutico , Estudos Retrospectivos , Hemoglobinas Glicadas , COVID-19/complicações , Inibidores da Dipeptidil Peptidase IV/uso terapêutico , Insulina Regular Humana/uso terapêutico , Hospitais , Insuficiência Renal/induzido quimicamente , Insuficiência Renal/complicações , Insuficiência Renal/tratamento farmacológico
2.
Br J Pharmacol ; 175(1): 53-66, 2018 01.
Artigo em Inglês | MEDLINE | ID: mdl-29053168

RESUMO

BACKGROUND AND PURPOSE: The advanced glycation end products (AGEs) participate in the pathogenesis of diabetic nephropathy (DN) by promoting renal inflammation and injury. L-carnosine acts as a quencher of the AGE precursors reactive carbonyl species (RCS), but is rapidly inactivated by carnosinase. In this study, we evaluated the effect of FL-926-16, a carnosinase-resistant and bioavailable carnosine derivative, on the onset and progression of DN in db/db mice. EXPERIMENTAL APPROACH: Adult male db/db mice and coeval db/m controls were left untreated or treated with FL-926-16 (30 mg·kg-1 body weight) from weeks 6 to 20 (prevention protocol) or from weeks 20 to 34 (regression protocol). KEY RESULTS: In the prevention protocol, FL-926-16 significantly attenuated increases in creatinine (-80%), albuminuria (-77%), proteinuria (-75%), mean glomerular area (-34%), fractional (-40%) and mean (-42%) mesangial area in db/db mice. This protective effect was associated with a reduction in glomerular matrix protein expression and cell apoptosis, circulating and tissue oxidative and carbonyl stress, and renal inflammatory markers, including the NLRP3 inflammasome. In the regression protocol, the progression of DN was completely blocked, although not reversed, by FL-926-16. In cultured mesangial cells, FL-926-16 prevented NLRP3 expression induced by RCS but not by the AGE Nε -carboxymethyllysine. CONCLUSION AND IMPLICATIONS: FL-926-16 is effective at preventing the onset of DN and halting its progression in db/db mice by quenching RCS, thereby reducing the accumulation of their protein adducts and the consequent inflammatory response. In a future perspective, this novel compound may represent a promising AGE-reducing approach for DN therapy.


Assuntos
Carnosina/uso terapêutico , Nefropatias Diabéticas/patologia , Nefropatias Diabéticas/prevenção & controle , Dipeptidases/uso terapêutico , Progressão da Doença , Animais , Disponibilidade Biológica , Carnosina/análogos & derivados , Células Cultivadas , Nefropatias Diabéticas/metabolismo , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Distribuição Aleatória
3.
ACS Chem Neurosci ; 7(8): 1130-40, 2016 08 17.
Artigo em Inglês | MEDLINE | ID: mdl-27244291

RESUMO

Kyotorphin (KTP) is an endogenous peptide with analgesic properties when administered into the central nervous system (CNS). Its amidated form (l-Tyr-l-Arg-NH2; KTP-NH2) has improved analgesic efficacy after systemic administration, suggesting blood-brain barrier (BBB) crossing. KTP-NH2 also has anti-inflammatory action impacting on microcirculation. In this work, selected derivatives of KTP-NH2 were synthesized to improve lipophilicity and resistance to enzymatic degradation while introducing only minor changes in the chemical structure: N-terminal methylation and/or use of d amino acid residues. Intravital microscopy data show that KTP-NH2 having a d-Tyr residue, KTP-NH2-DL, efficiently decreases the number of leukocyte rolling in a murine model of inflammation induced by bacterial lipopolysaccharide (LPS): down to 46% after 30 min with 96 µM KTP-NH2-DL. The same molecule has lower ability to permeate membranes (relative permeability of 0.38) and no significant activity in a behavioral test which evaluates thermal nociception (hot-plate test). On the contrary, methylated isomers at 96 µM increase leukocyte rolling up to nearly 5-fold after 30 min, suggesting a proinflammatory activity. They have maximal ability to permeate membranes (relative permeability of 0.8) and induce long-lasting antinociception.


Assuntos
Analgésicos/farmacologia , Dipeptidases/farmacologia , Endorfinas/química , Endotélio/efeitos dos fármacos , Microcirculação/efeitos dos fármacos , Animais , Anti-Inflamatórios , Barreira Hematoencefálica , Dipeptidases/síntese química , Dipeptidases/uso terapêutico , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Endorfinas/farmacologia , Hiperalgesia/tratamento farmacológico , Leucócitos/efeitos dos fármacos , Masculino , Camundongos , Ratos , Fatores de Tempo
4.
Chem Biol Interact ; 203(1): 191-5, 2013 Mar 25.
Artigo em Inglês | MEDLINE | ID: mdl-22982776

RESUMO

Human liver prolidase, a metal-dependent dipeptidase, is being tested as a potential catalytic bioscavenger against organophosphorus (OP) chemical warfare nerve agents. The purpose of this study was to determine whether persistent and high-levels of biologically active and intact recombinant human (rHu) prolidase could be introduced in vivo in mice using adenovirus (Ad). Here, we report that a single intravenous injection of Ad containing the prolidase gene with a 6× histidine-tag (Ad-prolidase) introduced high-levels of rHu prolidase in the circulation of mice which peaked on days 5-7 at 159 ± 129 U/mL. This level of prolidase is ~120 times greater than that of the enzyme level in mice injected with Ad-null virus. To determine if all of Ad-prolidase-produced rHu prolidase was exported into the circulation, enzyme activity was measured in a variety of tissues. Liver contained the highest levels of rHu prolidase on day 7 (5647 ± 454 U/g) compared to blood or any other tissue. Recombinant Hu prolidase hydrolyzed DFP, a simulant of OP nerve agents, in vitro. In vivo, prolidase overexpression extended the survival of 4 out of 6 mice by 4-8h against exposure to two 1× LD(50) doses of DFP. In contrast, overexpression of mouse butyrylcholinesterase (BChE), a proven stoichiometric bioscavenger of OP compounds, protected 5 out of 6 mice from DFP lethality and surviving mice showed no symptoms of DFP toxicity. In conclusion, the results suggest that gene delivery using Ad is capable of introducing persistent and high levels of human liver prolidase in vivo. The gene-delivered prolidase hydrolyzed DFP in vitro but provided only modest protection in vivo in mice, delaying the death of the animals by only 4-8h.


Assuntos
Dipeptidases/genética , Dipeptidases/metabolismo , Adenoviridae/genética , Animais , Antídotos/metabolismo , Antídotos/uso terapêutico , Substâncias para a Guerra Química/metabolismo , Substâncias para a Guerra Química/toxicidade , Dipeptidases/uso terapêutico , Feminino , Expressão Gênica , Técnicas de Transferência de Genes , Vetores Genéticos , Humanos , Isoflurofato/metabolismo , Isoflurofato/toxicidade , Fígado/enzimologia , Camundongos , Compostos Organofosforados/metabolismo , Compostos Organofosforados/toxicidade , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Proteínas Recombinantes/uso terapêutico , Distribuição Tecidual
5.
J Appl Microbiol ; 113(2): 233-47, 2012 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-22512465

RESUMO

Prolidase is a multifunctional enzyme that possesses the unique ability to degrade imidodipeptides in which a proline or hydroxyproline residue is located at the C-terminal end. Prolidases have been isolated from archaea and bacteria, where they are thought to participate in proline recycling. In mammalian species, prolidases are found in the cytoplasm and function primarily to liberate proline in the final stage of protein catabolism, particularly during the biosynthesis and degradation of collagen. Collagen comprises nearly one-third of the total protein in the body, and it is essential in maintaining tissue structure and integrity. Prolidase deficiency (PD), a rare autosomal recessive disorder in which mutations in the PEPD gene affect prolidase functionality, tends to have serious and sometimes life-threatening clinical symptoms. Recombinant prolidases have many applications and have been investigated not only as a possible treatment for PD, but also as a part of anti-cancer strategies, a component of biodecontamination cocktails and in the dairy industry. This review will serve to discuss the many in vivo functions of procaryotic and eucaryotic prolidases, as well as the most recent advances in therapeutic and biotechnological application of prolidases.


Assuntos
Biotecnologia , Dipeptidases/metabolismo , Prolina/metabolismo , Animais , Archaea/enzimologia , Bactérias/enzimologia , Biodegradação Ambiental , Colágeno/metabolismo , Dipeptidases/deficiência , Dipeptidases/uso terapêutico , Terapia de Reposição de Enzimas , Indústria Alimentícia , Humanos , Estrutura Terciária de Proteína
6.
Eur J Pharm Biopharm ; 70(1): 58-65, 2008 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-18547793

RESUMO

Prolidase loaded chitosan nanoparticles were set up in order to suggest an innovative therapeutic approach for Prolidase Deficiency (PD), a rare autosomal inherited disorder of the connective tissue. The satisfactory drug loading efficiency (42.6+/-2.1%) as well as the suitable physical characteristics (mean diameter of 365.5+/-35.1 nm and a positive zeta-potential of 17.94+/-0.12 mV) was achieved. In order to verify the compatibility of the chitosan nanoparticles with cells, the influence of the nanoparticles on the growth and the viability (MTT assay) of cultured skin fibroblasts were determined: the nanoparticles showed a good biocompatibility up to 5 microg of chitosan/10,000 fibroblasts. Uptake of chitosan nanoparticles by fibroblasts was verified by confocal microscopy using FITC-labelled chitosan nanoparticles. The ex vivo experiments were performed by incubating different amounts of prolidase loaded chitosan nanoparticles with skin human fibroblasts from PD patients for scheduled times. The restored prolidase activity was quantitatively monitored by a capillary electrophoretic method and confirmed by cells morphological observations. Standing from the nanoparticles internalization, the enzymatic activity was progressively restored reaching the best value (about 66%) after 5 days of co-incubation. Moreover, prolidase loaded chitosan nanoparticles permitted to restore prolidase activity in PD fibroblasts for a prolonged period of time (8 days).


Assuntos
Erros Inatos do Metabolismo dos Aminoácidos/tratamento farmacológico , Quitosana/química , Dipeptidases/farmacologia , Portadores de Fármacos , Fibroblastos/efeitos dos fármacos , Nanopartículas , Erros Inatos do Metabolismo dos Aminoácidos/enzimologia , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Química Farmacêutica , Quitosana/toxicidade , Dipeptidases/química , Dipeptidases/deficiência , Dipeptidases/uso terapêutico , Relação Dose-Resposta a Droga , Eletroforese Capilar , Endocitose , Estabilidade Enzimática , Fibroblastos/enzimologia , Humanos , Microscopia Confocal , Tamanho da Partícula , Solubilidade , Fatores de Tempo
7.
Int J Pharm ; 358(1-2): 230-7, 2008 Jun 24.
Artigo em Inglês | MEDLINE | ID: mdl-18455892

RESUMO

The first aim of this work was to perform site-directed PEGylation of the enzyme prolidase at sulphydril groups by methoxy-polyethylene glycol-maleimide (Mal-PEG, Mw 5000 Da) in order to obtain a safe conjugation product more stable than the native enzyme. Prolidase is a cytosolic aminoacyl-l-proline hydrolase whose deficiency causes the onset of rare autosomal recessive disorder called prolidase deficiency (PD). The second purpose of this work was to investigate whether biodegradable chitosan nanoparticles loaded with PEGylated prolidase could be effective in releasing active enzyme inside fibroblasts as a possible therapeutic approach for PD. The SDS-PAGE analysis and the ESI-MS spectra confirmed the presence of the PEGylated prolidase: in particular the main conjugation product (m/z=about 65,000 Da) corresponded to the enzyme with two residues of Mal-PEG. In this study it was demonstrated the lack of toxicity (MTT assay) and the prolonged activity (40.6+/-2.6% after 48h of incubation at 37 degrees C) of the PEGylated enzyme. The PEGylated prolidase loaded chitosan nanoparticles had spherical shape, narrow size distribution (271.6+/-45.5 nm), a positive zeta-potential (15.93+/-0.26 mV) with a good preparation yield (54.6+/-3.6%) and protein encapsulation efficiency (44.8+/-4.6%). The ex vivo evaluation of prolidase activity on PD fibroblasts individuated a good level of prolidase activity replaced (about 72% after only 2 days of incubation) up to 10 days with improved morphological cell features.


Assuntos
Dipeptidases/administração & dosagem , Dipeptidases/uso terapêutico , Polietilenoglicóis/química , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Dipeptidases/química , Portadores de Fármacos , Composição de Medicamentos , Sistemas de Liberação de Medicamentos , Eletroforese em Gel de Poliacrilamida , Fibroblastos/efeitos dos fármacos , Humanos , Maleimidas/química , Microscopia Eletrônica de Transmissão , Nanopartículas , Espectrometria de Massas por Ionização por Electrospray , Compostos de Sulfidrila/química
8.
Mol Pharm ; 2(1): 37-46, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15804176

RESUMO

Bioinformatics tools such as Perl, Visual Basic, Cluster, and TreeView were used to analyze public gene expression databases in order to identify potential enzyme targets for prodrug strategies. The analyses indicated that prolidase might be a desirable enzyme target based on its differential expression in melanoma cancer cell lines and its high substrate specificity for dipeptides containing proline at the carboxy terminus. RT-PCR expression of prolidase and hydrolytic activity against N-glycyl-l-proline (GLY-PRO), a standard substrate of prolidase, determined in tumor cell lines, exhibited a high correlation (r(2) = 0.95). These results suggest the possibility of targeting prolidase with prodrugs of anticancer agents for enhanced selectivity. The feasibility of such a scenario was tested by (a) synthesizing prodrugs of melphalan that comprised linkage of the carboxy terminus of the l-phenylalanine moiety of melphalan to the N-terminus of l and d stereoisomers of proline and (b) determining their bioconversion and antiproliferative activities in SK-MEL-5 cells, a melanoma cancer cell line with high expression levels of prolidase. The results of hydrolysis studies of the l- and d-proline prodrugs of melphalan, designated as prophalan-l and prophalan-d, respectively, indicated a approximately 7-fold higher rate of activation of prophalan-l compared to prophalan-d in SK-MEL-5 cell homogenates. Prophalan-l exhibited cytotoxicity (GI(50) = 74.8 microM) comparable to that of melphalan (GI(50) = 57.0 microM) in SK-MEL-5 cells while prophalan-d was ineffective, suggesting that prolidase-specific activation to the parent drug may be essential for cytotoxic action. Thus, melphalan prodrugs such as prophalan-l that are cleavable by prolidase offer the potential for enhanced selectivity by facilitating cytotoxic activity only in cells overexpressing prolidase.


Assuntos
Dipeptidases/uso terapêutico , Desenho de Fármacos , Melanoma/tratamento farmacológico , Melfalan/análogos & derivados , Pró-Fármacos/uso terapêutico , Prolina/análogos & derivados , Prolina/química , Sequência de Aminoácidos , Antineoplásicos , Células CACO-2 , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Colorimetria , Estudos de Viabilidade , Humanos , Células K562 , Melfalan/síntese química , Melfalan/química , Melfalan/metabolismo , Melfalan/uso terapêutico , Análise de Sequência com Séries de Oligonucleotídeos , Pró-Fármacos/síntese química , Pró-Fármacos/química , Pró-Fármacos/metabolismo , Prolina/síntese química , Prolina/metabolismo , Prolina/uso terapêutico , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Especificidade por Substrato
9.
J Control Release ; 102(1): 181-90, 2005 Jan 20.
Artigo em Inglês | MEDLINE | ID: mdl-15653144

RESUMO

Prolidase is a cytosolic exopeptidase whose deficiency causes the development of a rare autosomal recessive disorder known as Prolidase Deficiency (PD). The main manifestations of PD are intractable ulcerations of the skin, recurrent infections and mental retardation. At this time only a hazardous and expensive chronic therapy based on blood transfusions is the suggested treatment for PD. The aim of this work was to investigate the capability of utilizing liposomes as enzyme carriers: these vesicular systems have been recently evaluated as protein carriers for their potential in terms of "in vivo" localization, drug release and for protein stabilization in biological fluids. Liposomes were prepared, with a 1:1 PC:Col molar ratio with or without DSPE-PEG, by a thin-film hydration. Ex-vivo experiments were performed, incubating prolidase loaded liposomes with cultured fibroblasts from PD patients and from controls, to determine the amount of active enzyme delivered to cells. Evaluation of liposomes toxicity on cultured skin fibroblasts showed that liposomes did not interfere with cellular growth. Results showed that all the active prolidase encapsulated in the liposomes was completely vehiculated inside fibroblasts after 6 days incubation. SEM analysis suggests that prolidase is vehiculated inside the cell through liposome endocytosis.


Assuntos
Dipeptidases/deficiência , Dipeptidases/uso terapêutico , Sistemas de Liberação de Medicamentos/métodos , Fibroblastos/efeitos dos fármacos , Líquido Intracelular/efeitos dos fármacos , Células Cultivadas , Endocitose , Fibroblastos/enzimologia , Humanos , Líquido Intracelular/enzimologia , Lipossomos
10.
Pediatr Dermatol ; 13(1): 58-60, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-8919529

RESUMO

Prolidase deficiency is a hereditary enzyme deficiency characterized dermatologically by chronic recurrent ulcers and scarring due to increased skin fragility. It has been speculated that the enzyme deficiency causes a relative deficiency of proline in the wounds of these patients and negatively affects clinical healing. Two ulcers in a 17-year-old girl with established prolidase deficiency were treated for 12 weeks with ointments containing amino acids in an open study comparing the effects of 5% proline and a combination of 5% proline plus 5% glycine. Both ointments caused significant reduction of the ulcer size (p < 0.02), but the 5% proline-5% glycine mixture caused a more rapid reduction (0.01 < p < 0.02). The results confirm previous findings in this rare inborn error of metabolism.


Assuntos
Dipeptidases/uso terapêutico , Úlcera Cutânea/tratamento farmacológico , Administração Tópica , Adolescente , Doença Crônica , Dipeptidases/administração & dosagem , Dipeptidases/deficiência , Feminino , Humanos , Pomadas/administração & dosagem , Pomadas/uso terapêutico , Úlcera Cutânea/diagnóstico , Úlcera Cutânea/etiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...